Located in Princeton, New Jersey, Soligenix has earned a reputation as a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases. Today, the young company took a major step towards prominence with the announcement that Kevin Horgan, MD, has been appointed the company’s Senior Vice President and Chief Medical Officer.
Dr. Horgan brings with him a distinguished career of over 25 years of excellence in both the industry and the field of academia. Dr. Horgan has over 40 publications in peer-reviewed journals including the New England Journal of Medicine, Nature, Journal of Immunology, Journal of Clinical Oncology, and Gastroenterology. Most recently, Dr. Horgan was employed with GE Healthcare as Head of Internal Medicine R&D in molecular diagnostics after a successful career at Merck.
At Soligenix, Dr. Horgan will lead the company’s clinical research with primary focus on the execution and completion of its confirmatory Phase 3 clinical trial of orBec® (oral beclomethasone dipropionate or BDP) in the treatment of acute gastrointestinal (GI) GVHD.
orBec is the lead product of the company and is a potent, locally acting corticosteroid being developed for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of hematopoietic cell transplantation. orBec is currently the subject of a $1.2 million FDA Orphan Products Grant-supported confirmatory Phase 3 clinical trial for the treatment of acute GI GVHD.
Commenting on what the addition of Dr. Horgan will mean to the future of Soligenix, Christopher J. Schaber, PhD., who serves as the President and CEO, was quoted as saying, “We are delighted to welcome Kevin to our team, as he will leverage his extensive drug development expertise in leading our GVHD and gastrointestinal clinical programs. His clinical experience with gastrointestinal inflammation and a background in cellular immunology will be instrumental to us as we advance orBec to Phase 3 completion in acute GI GVHD and beyond.”
With the potential of orBec and the competence of Dr. Horgan, this could be fantastic news for both shareholders of Soligenix and the medical community as a whole.
To learn more about Soligenix, visit the company website at: www.soligenix.com